key: cord-0788098-jcp3ya5s
authors: Padmaprakash, K.V.; Thareja, Sandeep; Raman, Nishant; Sowmya Karantha, C.; Muthukrishnan, J.; Vardhan, Vasu
title: “Does Transaminitis Predict Severity and Mortality in COVID 19 Patients?”
date: 2022-01-31
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2022.01.004
sha: ad24226d101630f8fac9d243751e8dd3032ac8e4
doc_id: 788098
cord_uid: jcp3ya5s

INTRODUCTION: The most dreaded pandemic grappling world now, the Coronavirus Disease 2019 (COVID-19), chiefly involves the respiratory system; nevertheless, it is a multisystem disorder. Its involvement of the hepatic system is considerable; however, still emerging are its clinical implications and effects on morbidity and mortality. The aim of this study is to report on the various aspects of its hepatic involvement by describing the alterations in tests of liver function and its significance in the disease outcome in a cohort of hospitalized COVID-19 patients at a tertiary centre in northern India. METHODS: This is a retrospective cohort study conducted in a tertiary-care hospital in northern India. All confirmed hospitalized COVID-19 cases aged 15 and above from Apr till Oct 2020 with no pre-existing liver disease were included. The primary endpoint was death at 28 days. Statistical analysis included descriptive analysis, sensitivity-specificity, and univariable and multivariable regression analysis as well as survival analysis. RESULTS: A total of 708 COVID-19 patients fulfilled the inclusion criteria included 561 (79.2%) males and 147 (20.8%) females. The median age was 49 (IQR=25) years. Mild and moderate/severe disease were seen in 508 (71.8%) and 200 (28.2) patients respectively. Serum bilirubin, Aspartate-aminotransferase (AST) and Alanine-aminotransferase (ALT) were elevated in 6.92%, 69.91% and 80.22% of patients respectively. In univariable logistic regression, AST [odds ratio; OR 1.008 95% CI (1.005-1.012) per 1 IU/L increase] and ALT [OR 1.005 95% CI (1.002-1.007) per 1 IU/L increase] were significantly associated with the odds of moderate-to-severe disease but only AST was significant after adjustment to age, sex, and comorbidity [adjusted odds ratio; aOR 1.007 95% CI (1.003-1.011) per 1IU/L increase]. Serum albumin was negatively associated with the odds of moderate to severe disease and remained significant in the adjusted model [aOR 0.217 95%CI (0.149-0.316) per 1g/dL increase]. Ninety-six patients succumbed to illness [case fatality rate; CFR 13.6%). In adjusted Cox Proportional-Hazards Model for mortality, AST [adjusted hazard ratio; aHR 1.002 95% CI (1.000-1.003) per 1 IU/L increase] and serum albumin [aHR 0.396 95% CI (0.285-0.549) per 1g/dL increase] showed significant association with mortality. CONCLUSION: Liver function abnormalities are common in COVID 19 patients. In particular, AST and serum albumin levels are effective predictors of disease severity and mortality and can be used as markers of fatal disease in the management as well as prognostication of COVID-19.

Coronavirus Disease 2019 , the pandemic of the 21 st century, has created a significant burden on health care resources, infrastructures, and the world economy. No country has been spared.

systems as well, such as the gastrointestinal tract, liver, and kidneys along with neurological and haematological manifestations.

An initial cohort study describing the epidemiological and clinical characteristics of 99 cases of COVID-19 pneumonia in Wuhan, China revealed elevated levels of the liver enzyme alanine aminotransferase (ALT) in 28% and that of total bilirubin in 18% of patients. 1 With no direct cytopathic effects being observed on liver biopsy specimens obtained from fatal cases, the exact mechanism of liver damage in COVID-19 was not clear. 2, 3 Subsequently, numerous studies have shown varying degrees of liver damage in COVID-19 patients, with a prevalence ranging from 15-65%. [4] [5] [6] [7] [8] [9] [10] However, the studies reporting on liver damage and abnormality of liver function tests associated with COVID-19 are small and mostly inconclusive in reporting the prognostic significance of these abnormalities. The present study reports on the characteristics of liver function abnormalities and their significance in disease severity and outcomes in a large cohort of 708 COVID-19 patients hospitalized in a tertiary center in northern India

This retrospective cohort study included 708 real-time reverse transcription-polymerase chain reaction (RT PCR) confirmed COVID-19 patients who were 15 years or older and were hospitalized in a tertiary hospital in northern India over a 6-month period from April to October 2020. Cases that did not have complete data were excluded. Data collected included demographic data, signs and symptoms, comorbidities, vitals at admission, inclusive of pulse rate, blood pressure and oxygen saturation by pulse oximetry (SpO2); and data on the outcome (i.e., discharge or death). History of pre-existing liver disease and alcohol consumption was recorded. Routine laboratory tests at admission were done on the day of admission and were inclusive of complete blood count (CBC) including total leukocyte-count (TLC), hemoglobin (Hb), platelet count (PLT); and liver and renal function tests comprising of serum bilirubin, aspartate-transaminase (AST), alaninetransaminase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), serum total protein, serum albumin, and serum creatinine. Viral hepatitis screening was done with hepatitis B surface antigen (HbSAg) and anti-hepatitis C antibody in addition to human immunodeficiency virus (HIV) by rapid test

Markers of inflammation such as ferritin and C-reactive protein (CRP) were investigated for, and prothrombin time (PT) was measured, and international normalized ratio (INR) estimated as and when indicated. Those who had abnormal liver functions underwent ultrasound imaging of the abdomen to rule out underlying chronic liver ailments such as hepatic steatosis, biliary obstruction. Markers for hepatitis A

and Hepatitis E were done if indicated.

Clearance from the ethical committee was obtained for the study.

J o u r n a l P r e -p r o o f 11 Based on national guidelines, the patients were categorized into mild, moderate, and severe disease using clinical parameters. Mild disease included patients with uncomplicated upper respiratory tract symptoms such as fever, sore throat, cough, malaise, and headache without evidence of breathlessness or hypoxia. Patients with an oxygen-saturation of 90-94% or respiratory rate more than or equal to 24 breaths per minute were categorized as moderate disease, and those who had an oxygen saturation of less than 90% or a respiratory rate of more than 30 breaths per minute with clinical signs of pneumonia constituted severe disease. 12 As per American College of Gastroenterology (ACG) guidelines, ALT and AST levels up to 33 IU/L for men and up to 25 IU/L for women were considered normal. 13 Statistical analysis:

Demographic, clinical parameters, and outcomes were initially analyzed using descriptive statistics.

Continuous variables were presented as median and interquartile range (IQR) and were compared by Mann-Whitney U test. Categorical variables were presented as percentages and as frequency distribution and compared by Chi-square tests. For continuous variables, receptor operation curve (ROC) curves were plotted for sensitivity-specificity analysis. Multiple logistic regression analysis for disease severity at admission was J o u r n a l P r e -p r o o f used to determine the predictive effect of deranged liver function tests with odds ratio (OR) and 95%

confidence intervals (CI) being reported. Survival analysis was done using Cox-proportional hazards regression. Univariable models were adopted to evaluate independent risk factors pertaining to mortality.

Multivariable analysis using backward elimination was done adjusting for potential confounding effects of other parameters or factors, the results being reported as hazards ratio (HR) and 95% CI. A p-value of less than 0.05 was considered to be statistically significant at 95% CI. For data handling and analysis, MS Excel 2016 (Microsoft Corporation) and SPSS 23 for Windows (IBM SPSS Statistics for Windows Version 23.0

Armonk NY: IBM Corp) were used, respectively.

A total of 708 patients fulfilled the inclusion criteria. respectively. The demographic profile and baseline investigations at admissions are shown in Table 1 .

The median (IQR) levels of total bilirubin, AST, ALT, ALP, GGT, total protein, and serum albumin are presented in Table 1 .

Total bilirubin. Total bilirubin was elevated in 49 patients (6.92%). It was between 1-2 mg/dL in 35(4.94%) patients, 2-3 mg/dL in 3(0.42%) patients and more than 3 mg/dL in 11 patients (1.55%). Among 708 patients, 200 (28.2%) had moderate to severe disease at admission. Significant differences existed in the levels of liver function tests, including serum bilirubin, AST, ALT, and serum albumin, with levels of these markers of liver injury being higher in patients with moderate to severe disease ( Table 3) . The results of the univariable and multivariable logistic regression for predictors of disease severity are shown in Table 4 ).

A total of 96 patients succumbed to illness (case fatality rate, CFR 13.6%). Significant differences in the levels of total bilirubin, AST, and ALT were observed between survivors and non-survivors ( Table 3) . The sensitivity and specificity of an abnormal AST to predict mortality was respectively 90.6% and 67%. But its positive predictive value (PPV) was only 17.5 %, the negative predictive value (NPV) being 95.73%. Similarly, an abnormal ALT predicted mortality with a sensitivity of 84.4% and a specificity of 89.3%, with PPV of 14.3%

and NPV of 89.3%.

The results of the univariable and multivariable Cox proportional hazard regression are presented in Table 5 ). The ROC curve revealed an AUC of 0.158, indicating a relatively good prognostic value (Figure 2 ).

This is one of the largest studies addressing liver dysfunction in hospitalized patients with COVID-19.

This study attempts to systematically evaluate the impact of liver function profile at admissions on the severity of COVID 19 at admission and further analyses its prognostic role.

The prevalence of comorbidities in our study was 44.6% which was similar to studies from Wuhan,

where it was 37.3% 14 , and an Indian study which showed 47.11% patients having at least one comorbidity 15.

The median AST and ALT levels in our study were 41 (IQR 35.8) IU/L and 50 (IQR 45.8) IU/L, respectively, whereas a study from China involving 1141 patients the median AST and ALT were 65.8 ± 12.7 IU/L and 66.4 ± 13.2 IU/L respectively 16 which were higher.

AST levels were abnormally high in 69.91% of patients in our study, corroborating with the results of an early Indian study involving 170 patients wherein raised liver enzymes were observed in 58.5%. 17 Similarly, in a large study from the US involving 5700 patients, AST levels were reported to be elevated in 58.4% patients. 8 In comparison, multiple Chinese cohort studies reported the prevalence of elevated AST levels in COVID-19 patients to be ranged between 4% to 53%. 18 In a systematic review of 6537 patients, elevated AST levels were observed in 53.3% patients. 19 

Our study finds AST and ALT to be significantly associated with the odds of moderate-to-severe disease in the univariable logistic regression. However, only AST was significant after adjustment for age, sex, and comorbidity status, with AST being associated with 0.7% greater odds per 1 IU/L increase in its 

A large meta-analysis of 20 retrospective studies with 3428 COVID-19 patients revealed that higher levels of ALT, AST, and bilirubin were associated with a significant increase in the severity of COVID-19

infection. 25 . Another large study estimated a ninefold risk of severe COVID-19 infection in patients with liver injury. 26 The reason for liver enzyme abnormalities have been postulated to be multifactorial. Hypoalbuminemia has been described in severe COVID-19 patients and may not parallel changes in AST and ALT. In a retrospective cohort of 299 patients, 106 (35.5%) patients had low albumin, with significant differences in the albumin levels between survivors and non-survivors (37.6 g/L vs. 30.5 g/L). 28 In our study, in the multivariable Cox proportional hazard regression, only the AST and serum albumin were significant predictors of mortality. A Chinese study showed AST to be a potential diagnostic marker, and its level was significantly higher in non-survivors compared with survivors, with its ROC curve revealing an AUC of 0.854 indicating its prognostic value. 9 Another meta-analysis linked elevated admission levels of these markers to patient mortality. 29 Albumin levels have also been reported in other studies to be an independent predictive factor for mortality. 23 In a meta-analysis of factors associated with disease outcomes in 1990

patients hospitalized COVID-19, hypoalbuminemia was observed to be associated with severe disease as well as death. 30 Serum albumin is a good prognostic marker and reflects not only liver function but also the nutritional status. Additionally, it is also a negative acute phase reactant which correlates with immune markers. 29

Strength and Limitations. This study provides results from an in-depth analysis of data from a large cohort of patients and involving a considerable number of risk factors on the association of deranged liver function tests on COVID-19 severity and mortality. Routinely available lab tests such as AST and albumin can be used to prognosticate the disease among in hospitalized patients which, at the same time, is cost economical as well as time accurate. The AST and ALT as negative predictive value is unique to our study. Limitations of our study include its retrospective nature and absence of pathological or radiological correlation. As the study included patients admitted to the hospital, the data involves a slight under-representation of patients with milder disease.

Abnormalities in liver function, being observed in over 80% of hospitalized COVID-19 patients is indeed a common phenomenon, however, its association with disease severity and mortality is strong and statistically significant. In particular, elevated AST levels and hypoalbuminemia are effective indicators of J o u r n a l P r e -p r o o f disease severity and mortality. Our study advocates the utilization of these readily available laboratory indices in triage, management, and prognostication of patients with COVID-19 pneumonia. 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv

Clinical Characteristics of Covid-19 in New York City

Digestive Manifestations in Patients Hospitalized With Coronavirus Disease

Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network

COVID-19 and liver dysfunction: A systematic review and meta-analysis of retrospective studies

Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area

Clinical Characteristics of Coronavirus Disease 2019 in China

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Division) (EMR. CLINICAL MANAGEMENT PROTOCOL: COVID-19.; 2020. Accessed

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease

Clinical Characteristics, Comorbidities,and Outcome among 365 Patients of Coronavirus Disease 2019 at a Tertiary Care Centre in Central India

Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)

COVID-19 associated variations in liver function parameters: a retrospective study

A meta-analysis of the impact of COVID-19 on liver dysfunction

Clinical Characteristics and Diagnostic Challenges of COVID−19: An Update From the Global Perspective

Prevalence of liver injury in 445 patients with Corona Virus Disease-19-Single-centre experience from southern India

Clinical Features of COVID-19-Related Liver Functional Abnormality

Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U

Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China

Involvement of liver in COVID-19: systematic review and metaanalysis

COVID-19: Abnormal liver function tests

Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity

COVID-19 and liver disease: mechanistic and clinical perspectives

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease